A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

[21] Novello S(2016)Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status J Clin Oncol 34 v653-1235

[22] Huber RM(2019)1586TiP - phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ) Ann Oncol 30 2274-509

[23] Gettinger SN(2019)Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control Thorac Cancer 10 1229-929

[24] Popat S(2004)A note on competing risks in survival data analysis Br J Cancer 91 496-1367

[25] Huang SH(1999)A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 917-1265

[26] Satagopan JM(2017)First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Lancet 389 1357-e94

[27] Fine JP(2017)ASCEND-8: a randomized phase 1 study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung Cancer (NSCLC) J Thorac Oncol 12 1255-6060

[28] Gray RJ(2019)Efficacy and safety of Ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study J Thorac Oncol 14 e77-undefined

[29] Soria JC(2016)Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK inhibitor(s) failure in advanced ALK positive non-small-cell lung Cancer: analysis and literature review Clin Lung Cancer 17 120ra17-undefined

[30] Cho BC(2012)Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci Transl Med 4 6051-undefined

[21] Novello S(2016)Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status J Clin Oncol 34 v653-1235

[22] Huber RM(2019)1586TiP - phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ) Ann Oncol 30 2274-509

[23] Gettinger SN(2019)Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control Thorac Cancer 10 1229-929

[24] Popat S(2004)A note on competing risks in survival data analysis Br J Cancer 91 496-1367

[25] Huang SH(1999)A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 917-1265

[26] Satagopan JM(2017)First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Lancet 389 1357-e94

[27] Fine JP(2017)ASCEND-8: a randomized phase 1 study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung Cancer (NSCLC) J Thorac Oncol 12 1255-6060

[28] Gray RJ(2019)Efficacy and safety of Ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study J Thorac Oncol 14 e77-undefined

[29] Soria JC(2016)Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK inhibitor(s) failure in advanced ALK positive non-small-cell lung Cancer: analysis and literature review Clin Lung Cancer 17 120ra17-undefined

[30] Cho BC(2012)Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci Transl Med 4 6051-undefined